Reading Time: 4 minutesIn Chicago, it’s the beginning of the third day of the International Symposium on ALS/MND. I feel that I’ve become almost institutionalised: I get up,
Author: Kiran Goyal
I work as a Research Officer within the MND Association to help organise the International Symposium and communicating the latest updates of MND research across our social media platforms. I graduated with a master's degree in Neuroscience from Cardiff University in 2023. I have previously supported the awareness of Fragile X syndrome within the UK.
Reading Time: 3 minutesA very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many
Reading Time: 2 minutesMany congratulations to Rosa Rademakers from Mayo Clinic Florida USA, winner of this year’s Paulo Gontijo Young Investigator award. She won the award for her
Reading Time: 3 minutesThe symposium session ‘Carer and Family Support’ provided a platform to better understand the role that informal carers play in the lives of people with
Reading Time: 3 minutesTrying to understand what the different underlying factors are towards developing MND has always been a goal for ALS research. MND Association funded researcher and
Reading Time: < 1 minuteNovember has been an incredibly busy time for us, not because of Christmas, but because the 23rd International Symposium on ALS/MND is now only one week away!
Reading Time: 2 minutesWhilst I try and keep up to date with what’s going on in the field for the rest of the year, it definitely goes in
Reading Time: 4 minutesA collaborative American research group, led by Prof Aaron Gitler from Stanford University School of Medicine in California, has identified a potential therapeutic target for
Reading Time: 3 minutesThe phrase ‘Share nicely’ is one that I associate with children sharing their toys, sweets and perhaps even Wii time. However, it works well in
Reading Time: 3 minutesPromising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested